Healthcare Industry News: YONDELIS
News Release - October 5, 2006
Array BioPharma Appoints April H. Teitelbaum, MD, MS, FACP Vice President of Clinical Development - OncologyBOULDER, Colo., Oct. 5 (HSMN NewsFeed) -- Array BioPharma Inc. (Nasdaq: ARRY ) today announced the appointment of April H. Teitelbaum, MD, MS, FACP, to the newly created position of Vice President of Clinical Development - Oncology, effective October 4, 2006. Dr. Teitelbaum will oversee the medical strategy and clinical development of Array's oncology drug pipeline and will report to the company's Chief Executive Officer, Robert E. Conway.
"April's solid track record and experience in developing new cancer drugs will be invaluable to Array as we advance our extensive drug pipeline," said Mr. Conway. "April's expertise in running complex clinical trials will be a competitive advantage for Array as we are on track for having five drugs in clinical development by the end of 2006."
Over the last 16 years, Dr. Teitelbaum has held positions of increasing responsibility for clinical and strategic development of oncology therapeutics at several pharmaceutical and biotechnology companies including Amgen, Sequus Pharmaceuticals, Ligand, the Johnson and Johnson family of companies, and Kyowa Pharmaceuticals, Inc. She has been involved in clinical development, including registration strategies and expansion of label, for multiple oncology therapeutics including Neupogen, Doxil (for the treatment of relapsed ovarian cancer and multiple myeloma), and YONDELIS, which is currently in clinical trials for the treatment of recurrent soft tissue sarcoma as well as other malignancies. Dr. Teitelbaum also headed her own consulting company and has served as a consultant to several companies for development of novel oncology therapeutics. Before embarking on a career in pharmaceutical drug development, Dr. Teitelbaum was engaged in private practice, specializing in Hematology and Medical Oncology. While in practice, she served as an Investigator for several clinical trials and maintained academic appointments through both UCLA and USC.
Dr. Teitelbaum received her M.D. from Rush Medical College and an M.S. degree in erythropoietin physiology from New York University. She completed subspecialty training in both Hematology and Medical Oncology at USC Medical Center and UCLA School of Medicine and is a diplomat of the American Board of Internal Medicine, Hematology, and Medical Oncology.
About Array BioPharma:
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. Our proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. For more information on Array, please go to www.arraybiopharma.com.
Array BioPharma Forward-Looking Statement:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties, including those discussed in our annual report filed on form 10-K for the year ended June 30, 2006, and in other reports filed by Array with the Securities and Exchange Commission. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to continue to fund and successfully progress internal research efforts and to create effective, commercially viable drugs, our ability to achieve and maintain profitability, the extent to which the pharmaceutical and biotechnology industries are willing to in-license drug candidates for their product pipelines and to collaborate with and fund third parties for their drug discovery activities, our ability to out-license our proprietary candidates on favorable terms, risks associated with our dependence on our collaborators for the clinical development and commercialization of our out-licensed drug candidates, the ability of our collaborators and of Array to meet drug objectives, including clinical trials, tied to milestones and royalties, and our ability to attract and retain experienced scientists and management. We are providing this information as of October 5, 2006. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.
Source: Array BioPharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.